Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

ONRELTEA 0.33 % — DIN 02421208

BRIMONIDINE (BRIMONIDINE TARTRATE) : 0.33 % · GALDERMA CANADA INC · GEL · wholesale supply in Canada

Health Canada status: MARKETED

What is ONRELTEA?

ONRELTEA 0.33 % contains BRIMONIDINE (BRIMONIDINE TARTRATE) : 0.33 %. It is listed in the Health Canada Drug Product Database under DIN 02421208, held by GALDERMA CANADA INC, supplied as GEL for TOPICAL administration. Health Canada currently lists it as marketed, status dated 24-Mar-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is ONRELTEA used for?

ONRELTEA (brimonidine) Gel, 0.33% is indicated for the topical treatment of facial erythema of rosacea in adults 18 years of age or older.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

How much does Brimonidine cost around the world?

Brimonidine is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.

What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Belgium publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.

MarketPrice basis published thereBrandsPacks listedRange
United Statesacquisition440USD███.██
Australiaex-manufacturer39AUD███.██
Greeceproducer price (ex-factory)77EUR███.██
Belgiumpublic11EUR███.██
Bahrainretail (max)11BHD███.██
United Kingdomhospital11GBP███.██
Hungaryproducer price (ex-factory)11HUF███.██
Icelandmax wholesale11ISK███.██
MoroccoPPV (public price)11MAD███.██
South Africasingle exit price11ZAR███.██

63 pack listings across 21 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Brimonidine pack in that market, so a high figure is usually a larger pack rather than the same product.

Figures are held for the Nexara team. Cross-market prices are published on incompatible bases and are not an offer, a landed cost, or a guide to what any buyer can obtain. Nexara publishes which markets list the product and on what basis; the numbers stay internal.

Team sign-in

Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.

Ask Nexara for a landed Canadian price

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label0.33 %
Dosage formGEL
RouteTOPICAL
Pack configuration (monograph)commercially available in laminated plastic tubes with a high density polyethylene (HDPE) head and polypropylene (PP) child resistant closure in a pack size of 30 g. Physician samples are available in laminated plastic tubes with a high density polyethylene (HDPE) head and polypropylene (PP) non-child resistant closure in a pack size of 2 g.
StorageStore at room temperature (15°C to 30°C). Protect from freezing.

Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.

Substance and classification

Active substanceBrimonidine
ATC codeD11AX21
AHFS class84:80.00
Biosimilar biologicNo

Confirm the pack and get a price

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)02421208
DIN (unpadded, as printed on some documents)2421208
Brand nameONRELTEA
Generic / active ingredientBRIMONIDINE (BRIMONIDINE TARTRATE) : 0.33 %
Market authorization holderGALDERMA CANADA INC
Health Canada schedulePrescription
ATC codeD11AX21
ATC anatomical main groupD — Dermatologicals
ATC therapeutic subgroupD11AX
Current statusMARKETED
Status date24-Mar-2014
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

Is Brimonidine in shortage in Canada?

A Canadian shortage report is on file for a product containing this molecule: Active — reported by AA PHARMA INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.

Check availability for ONRELTEA

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

2 · Same class — other molecules in ATC D11AX

MoleculeCanadian brandsDINsMarketedSourceable
Pyrithione Zinc2 IN 1 ANTI-DANDRUFF SHAMPOO AND CONDITIONER · 2 IN 1 CONDITIONING DANDRUFF SHAMPOO · 2 IN 1 CONDITIONING DANDRUFF TREATMENT SHAMPOO · 2 IN 1 DANDRUFF RELIEF SHAMPOO & CONDITIONER · +343 more36367Yes
FinasterideAURO-FINASTERIDE 1MG · FINASTERIDE · JAMP FINASTERIDE TABLETS · MINT-FINASTERIDE · +5 more108Yes
Minoxidil, TopicalAPO-GAIN LIQ 20MG/ML · GEN-MINOXIDIL LIQ 2% · HAIR REGROWTH FORMULA · HAIR REGROWTH TREATMENT · +11 more167Yes
IvermectinPMS-IVERMECTIN · ROSIVER22Yes
HydroquinoneACTIVE 4 · AFRICAN GOLD SKIN DISCOLORATION FADE CRM 2% · AMBI EXTRA SKIN DISCOLORATION FADE CREAM · BANISHING CREAM · +63 more671Yes
BrimonidineONRELTEA11Yes
EflornithineVANIQA11Yes
Deoxycholic AcidBELKYRA11Yes
Other DermatologicalsDERMAGRAN II OINTMENT-ONT TOP 0.25% · SHUR-CLENS SOLN 20% · WITCH HAZEL30Not in Canada
MonobenzoneBENOQUIN CRM 20%10Not in Canada

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC D11A

ATC subgroupMoleculesDINsMarketed
D11AHAbrocitinib · Alitretinoin · Crisaborole · Delgocitinib · Dupilumab · +5 more2519
D11AFWart And Anti-Corn Preparations331
D11AAAntihidrotics3970
D11ACCetrimide · Medicated Shampoos · Others · Povidone-Iodine · Selenium Compounds · +1 more270

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

What else is ONRELTEA called?

The same molecule, Brimonidine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
AlphaganLatinAustralia, Morocco
CombiganLatinAustralia
EnidinLatinAustralia
BRIMOCTLatinSouth Africa
BRIMONDALOUSLatinBahrain
MirvasoLatinIceland

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for ONRELTEA

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 02421208. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.